Akriveia Therapeutics is discovering and developing the next generation of cancer immunotherapies. Akriveia's new agents offer the promise of a safer and more efficacious approach to harness a patient's own immune system to fight cancer. Akriveia was founded on the pioneering work of Professor John Williams at City of Hope and Professor Ulrich Rodeck at Thomas Jefferson University, experts in the fields of bioengineering and cancer therapeutic discovery.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/12/16 | $7,500,000 | Series A |
F-Prime Capital Partners | undisclosed |
